Research
Leerink Partners Initiates Coverage on Phathom Pharmaceuticals With Market Perform, $10 PT
Phathom Pharmaceuticals (PHAT) has an average rating of Buy and mean price target of $23.70, according to analysts polled by FactSet.
$PHAT
$PHAT
1 story mentioning PHATUpdated 15d ago
Every FINWIRES story that references PHAT, newest first.
What are analysts saying about PHAT?
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
